4DMedical (ASX:4DX) lifts lung surgery success from 46% to 76%

Blue Journal validation reframes CT VQ as a hospital margin story, not just an imaging upgrade

4DMedical (ASX:4DX) has finally landed the kind of peer-reviewed validation that respiratory imaging companies spend years chasing. A clinical study evaluating its CT VQ technology has been published in the American Journal of Respiratory and Critical Care Medicine, the field’s most influential journal.

Using CT VQ-style functional imaging to select patients for lung volume reduction surgery (LVRS) lifted the response rate from 46% to 76%. That is not a marginal improvement. That is the difference between a procedure many hospitals view as economically marginal and one that becomes a profitable, repeatable service line.

LVRS is a surgical treatment for severe emphysema where damaged portions of the lung are removed so the remaining tissue can function more effectively. The problem has always been picking the right patients. Get it wrong and you get complications, longer hospital stays and poor outcomes.

The study is being presented this week at the ATS 2026 Congress in Orlando, the largest respiratory medicine meeting in the world. For a company that has spent years building scientific credibility, the timing is about as good as it gets.

Why a 30-point swing in surgical outcomes changes the commercial story

The clinical numbers are striking, but the economic implications are what investors should focus on. Hospital margins on LVRS are notoriously sensitive to patient selection. A failed procedure means longer length of stay, more complications and a case that loses money rather than makes it.

If CT VQ can reliably push the success rate from below half to over three quarters, the procedure goes from being a clinically valuable but financially fragile service to a precision-led, high-margin program. That reframes the sales conversation for 4DMedical. It is no longer pitching an imaging upgrade, it is pitching a tool that protects contribution margin per surgical case.

Crucially, CT VQ derives its functional information from existing non-contrast CT scans. No new equipment, no contrast agents, no radioisotopes. That removes the biggest friction point in selling diagnostic technology into hospitals, which is the capital and workflow disruption.

What this validation does and does not prove

We think investors need to read the announcement carefully. The published study evaluated XV technology, the underlying physics that powers 4DMedical’s broader platform. The company is making the case that the findings are directly relevant to CT VQ because both extract similar functional metrics from CT imaging.

That is a reasonable read, but it is not the same as a CT VQ-specific randomised trial. Our concern is that some of the commercial heavy lifting still requires the company to translate this scientific credibility into actual hospital contracts and recurring SaaS revenue.

The good news is that the publication venue itself does meaningful work. Cardiothoracic surgeons and pulmonologists who would not have taken a marketing brochure seriously will read AJRCCM. That lowers the cost of every sales conversation 4DMedical has from here.

The ATS timing is doing real commercial work

Publishing this study to coincide with the ATS Congress is not an accident. ATS is where US thoracic surgery programs and radiology departments make their procurement shortlists for the year ahead. Having a peer-reviewed economic case in hand at the event matters.

The 21 May webinar featuring Dr Joseph Mammarappallil from Duke is a sensible follow-through. Duke is exactly the kind of advanced medical centre that anchors regional LVRS referral networks. Visible support from that calibre of institution travels.

What we will be watching is whether this scientific moment converts into named hospital deployments and disclosed SaaS revenue growth over the next two reporting periods.

The Investors Takeaway for 4DMedical

This is the most commercially relevant clinical validation 4DMedical has produced. A peer-reviewed paper in the field’s leading journal, presented at its largest congress, demonstrating a 30-point lift in surgical success rates is the foundation a commercial team needs.

The question now is execution. The economic case for hospitals is genuinely strong, but CT VQ still needs to demonstrate disclosed, recurring SaaS revenue traction tied to LVRS programs specifically. The next two halves of reporting will tell us whether the science has translated into the sales pipeline. Readers can find more in-depth coverage of ASX-listed respiratory and medical imaging names at stocksdownunder.

We think the publication materially de-risks the clinical narrative. It does not yet de-risk the commercial one.